Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTK7-targeted CAR-T cell therapy
- Development stage
- Preclinical
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PTK7-targeted CAR-T cell therapy is an investigational cellular immunotherapy designed to target Protein Tyrosine Kinase 7 (PTK7), a pseudokinase receptor in the Wnt signaling pathway that is highly expressed on cancer stem cells (CSCs) and various solid tumors. The therapy involves engineering a patient's T cells to express a chimeric antigen receptor (CAR) that specifically recognizes PTK7, leading to antigen-specific activation and tumor cell lysis. Preclinical studies have demonstrated efficacy in models of triple-negative breast cancer (TNBC), non-small-cell lung cancer (NSCLC), ovarian cancer, and neuroblastoma, particularly those with ATRX in-frame fusions which drive high PTK7 expression.
- Other names
- PTK7-CAR T cellsPTK-7-CAR T cellsPTK 7-CAR T cellsPTK7-targeted chimeric antigen receptor T-cell therapyPTK-7-targeted chimeric antigen receptor T-cell therapyPTK 7-targeted chimeric antigen receptor T-cell therapy
02
Targets
PTK7 (Protein tyrosine kinase 7)
Beyond the preview
Go deeper on PTK7-targeted CAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTK7-targeted CAR-T cell therapy.